<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d341" origId="Leucovorin"><sentence id="DrugDDI.d341.s0" origId="s0" text="Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients."><entity id="DrugDDI.d341.s0.e0" origId="s0.p0" charOffset="0-10" type="drug" text="Folic acid"/><entity id="DrugDDI.d341.s0.e1" origId="s0.p4" charOffset="47-60" type="drug" text="antiepileptic"/><entity id="DrugDDI.d341.s0.e2" origId="s0.p5" charOffset="71-84" type="drug" text="phenobarbital"/><entity id="DrugDDI.d341.s0.e3" origId="s0.p6" charOffset="86-95" type="drug" text="phenytoin"/><entity id="DrugDDI.d341.s0.e4" origId="s0.p8" charOffset="100-109" type="drug" text="primidone"/><entity id="DrugDDI.d341.s0.e5" origId="s0.p13" charOffset="165-174" type="drug" text="pediatric"/><pair id="DrugDDI.d341.s0.p0" e1="DrugDDI.d341.s0.e0" e2="DrugDDI.d341.s0.e1" interaction="?"/><pair id="DrugDDI.d341.s0.p1" e1="DrugDDI.d341.s0.e0" e2="DrugDDI.d341.s0.e2" interaction="?"/><pair id="DrugDDI.d341.s0.p2" e1="DrugDDI.d341.s0.e0" e2="DrugDDI.d341.s0.e3" interaction="?"/><pair id="DrugDDI.d341.s0.p3" e1="DrugDDI.d341.s0.e0" e2="DrugDDI.d341.s0.e4" interaction="?"/><pair id="DrugDDI.d341.s0.p4" e1="DrugDDI.d341.s0.e0" e2="DrugDDI.d341.s0.e5" interaction="?"/><pair id="DrugDDI.d341.s0.p5" e1="DrugDDI.d341.s0.e1" e2="DrugDDI.d341.s0.e2" interaction="?"/><pair id="DrugDDI.d341.s0.p6" e1="DrugDDI.d341.s0.e1" e2="DrugDDI.d341.s0.e3" interaction="?"/><pair id="DrugDDI.d341.s0.p7" e1="DrugDDI.d341.s0.e1" e2="DrugDDI.d341.s0.e4" interaction="?"/><pair id="DrugDDI.d341.s0.p8" e1="DrugDDI.d341.s0.e1" e2="DrugDDI.d341.s0.e5" interaction="?"/><pair id="DrugDDI.d341.s0.p9" e1="DrugDDI.d341.s0.e2" e2="DrugDDI.d341.s0.e3" interaction="?"/><pair id="DrugDDI.d341.s0.p10" e1="DrugDDI.d341.s0.e2" e2="DrugDDI.d341.s0.e4" interaction="?"/><pair id="DrugDDI.d341.s0.p11" e1="DrugDDI.d341.s0.e2" e2="DrugDDI.d341.s0.e5" interaction="?"/><pair id="DrugDDI.d341.s0.p12" e1="DrugDDI.d341.s0.e3" e2="DrugDDI.d341.s0.e4" interaction="?"/><pair id="DrugDDI.d341.s0.p13" e1="DrugDDI.d341.s0.e3" e2="DrugDDI.d341.s0.e5" interaction="?"/><pair id="DrugDDI.d341.s0.p14" e1="DrugDDI.d341.s0.e4" e2="DrugDDI.d341.s0.e5" interaction="?"/></sentence><sentence id="DrugDDI.d341.s1" origId="s1" text="Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration."><entity id="DrugDDI.d341.s1.e0" origId="s1.p20" charOffset="99-109" type="drug" text="leucovorin"/><entity id="DrugDDI.d341.s1.e1" origId="s1.p31" charOffset="234-246" type="drug" text="methotrexate"/><pair id="DrugDDI.d341.s1.p0" e1="DrugDDI.d341.s1.e0" e2="DrugDDI.d341.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d341.s2" origId="s2" text="However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate."><entity id="DrugDDI.d341.s2.e0" origId="s2.p36" charOffset="23-33" type="drug" text="leucovorin"/><entity id="DrugDDI.d341.s2.e1" origId="s2.p40" charOffset="88-100" type="drug" text="methotrexate"/><pair id="DrugDDI.d341.s2.p0" e1="DrugDDI.d341.s2.e0" e2="DrugDDI.d341.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d341.s3" origId="s3" text="Leucovorin may enhance the toxicity of 5-fluorouracil."><entity id="DrugDDI.d341.s3.e0" origId="s3.p41" charOffset="0-10" type="drug" text="Leucovorin"/><entity id="DrugDDI.d341.s3.e1" origId="s3.p45" charOffset="41-53" type="drug" text="fluorouracil"/><pair id="DrugDDI.d341.s3.p0" e1="DrugDDI.d341.s3.e0" e2="DrugDDI.d341.s3.e1" interaction="?"/></sentence></document>